Publications
258
Citations
5,247
Est. group size
—
Recurring co-author estimate
Active years
22
Publishing since 2005
Timothy A. Masterson studies the diagnosis and surgical treatment of testicular cancer, with a particular focus on retroperitoneal lymph node dissection (a surgery to remove lymph nodes in the back of the abdomen where these cancers spread). Much of the recent work explores circulating tumor DNA (fragments of cancer DNA found in the blood) as a biomarker to guide treatment decisions, alongside studies of surgical outcomes and cancer staging. The research also touches on broader urologic oncology topics such as bladder, prostate, and sarcoma cancers.
Publication activity has remained steady over the past decade, fluctuating between roughly 9 and 25 papers per year with an average of about 14 in the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Discontinuous Involvement of the Spermatic Cord by Germ Cell Tumors Should Not Be Considered Pathologic Stage M1
The American Journal of Surgical Pathology · 2026
- Diagnostic Accuracy of Circulating Tumor DNA to Predict Retroperitoneal Histology in Patients Treated With Retroperitoneal Lymph Node Dissection for Testicular Germ Tumor
European Urology · 2026
- Performance of circulating tumor DNA as a biomarker in testicular seminoma and non-seminomatous germ cell tumor patients undergoing primary retroperitoneal lymph node dissection.
Journal of Clinical Oncology · 2026
- Circulating tumor DNA performance in primary retroperitoneal lymph node dissection: A stage-based analysis.
Journal of Clinical Oncology · 2026
- Survivorship outcomes of stage I testis cancer management.
Journal of Clinical Oncology · 2026
- DISPARITIES IN UROLOGIC ONCOLOGY: ANALYSIS OF THE SOCIETY OF UROLOGIC ONCOLOGY FELLOWSHIP MATCH STATISTICS 2019–2024
Urologic Oncology Seminars and Original Investigations · 2025
- Histologic Concordance Between Post-chemotherapy RPLND and Orchiectomy When Performed Simultaneously: Insights Into the Blood-testis Barrier
Urology · 2025
- Retroperitoneal Nodal Distribution for Metastatic Seminoma: Is Modified Template Appropriate? A Retrospective Study
The Journal of Urology · 2025
- The role of primary RPLND in clinical stage IIA/B testicular germ cell tumor: a narrative review
Die Urologie · 2025
- Circulating tumor DNA as a prognostic biomarker to predict retroperitoneal histology in patients undergoing retroperitoneal lymph node dissection.
Journal of Clinical Oncology · 2025
- Reply by Authors
The Journal of Urology · 2025
- IP27-07 DOES A BLOOD-TESITS BARRIER EXIST?: VALUE OF ORCHIECTOMY AT THE TIME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION
The Journal of Urology · 2025
- IP27-10 CIRCULATING TUMOR DNA AS A PROGNOSTIC BIOMARKER TO PREDICT RETROPERITONEAL HISTOLOGY IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION
The Journal of Urology · 2025
- Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review
European Urology · 2024
- Retroperitoneal Lymph Node Dissection
Urologic Clinics of North America · 2024
- The Journal of Urology×45
- Journal of Clinical Oncology×34
- Urologic Oncology Seminars and Original Investigations×19
- European Urology×7
- Urology×7
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile